Project Type(s):
Clinical Research
Principal Investigator(s):
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.
Project Period:
June 18, 2020
Funding Type(s):
Private company/industry
Funder(s):
Eli Lilly and Company
Eli Lilly and Company
Geographic Area(s):
Alaska, Seattle/Puget Sound, University of Washington, Washington
Practice Type(s):
Outpatient
Patient Population(s):
Adults
Targeted Condition(s):
Cognitive Disorders
